Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. Photodynamic therapy using silicon phthalocyanine 4 may be effective against skin cancer.

PURPOSE: This phase I trial is studying the side effects and best dose of photodynamic therapy using silicon phthalocyanine 4 in treating participants with actinic keratosis, Bowen's disease, skin cancer, or stage I or stage II mycosis fungoides.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Case Comprehensive Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Silicon; Silicon phthalocyanine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of 1 of the following:

• Actinic keratosis

• Bowen's disease

• Squamous cell skin cancer

• Basal cell skin cancer

• Clinical stage IA, IB, IIA, or IIB mycosis fungoides

• Fitzpatrick skin type I-IV

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Not specified

Renal

• Not specified

Other

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patient must use effective contraception

• No diabetes mellitus

• No known hypersensitivity to ethanol or propylene glycol

• No significant history of photosensitivity, including diagnosis of any of the following:

• Porphyria

• Lupus erythematosus

• Xeroderma pigmentosum

• Severe polymorphous light eruption

• Solar urticaria

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• No concurrent chemotherapy

Endocrine therapy

• Not specified

Radiotherapy

• More than 2 weeks since prior anticancer radiotherapy

• No concurrent radiotherapy

Surgery

• Lesions must be healed after prior biopsy

Other

• More than 2 weeks since prior topical, local, or systemic anticancer therapy

• More than 2 weeks since prior anticancer phototherapy

• More than 2 weeks since prior photosensitizing medications, including any of the following:

• Tetracyclines

• Quinolones

• Psoralens

• Hydrochlorothiazide

• Furosemide

• Trimethoprim-sulfamethoxazole

• Griseofulvin

• Nalidixic acid

• Amiodarone

• Phenothiazines

• High-dose nonsteroidal anti-inflammatory drugs

• No other concurrent photosensitizing medications

• No concurrent therapeutic dose of warfarin that may cause excessive bleeding during skin biopsy